Photo : ru.gsk.com
the Russian producer of Serdix began production the first registration series of medicine for treatment of HIV of Tivikay (dolutegravir) Pharmaceutical company ViiV Healthcare (division of the British GlaxoSmithKline). The total volume of direct investments in the project makes about 300 million rubles without intellectual property.
to"We are very glad to progress of developments the project of local productions a preparation of Tivikay in partnership with company to Serdix. It is very important project for us which confirms our obligations for expansion of access to innovative therapy for the HIV-infected patients to Russian Federation, and we pay it special attention", – the vice-president and the head of the international region of Pharmaceutical company ViiV Healthcare Iacopo Andreoz, the visited Serdix plant told during productions the first registration series.
byOn production the first registration series of an anti-retrovirus preparation with active ingredient dolutegravir were involved both Russian, and the British experts. The made series was directed on the parallel analysis in Serdix laboratory and laboratory Pharmaceutical company ViiV Healthcare to United Kingdom. Results of laboratory tests showed identity made in Russian Federation a preparation with production of the foreign partner, and also confirmed a correctness carried out before harmonization of analytical techniques.
the Following stage of implementation of the project becomes transfer of transfer technologies to the main production lines of the Russian plant in the second half of the year 2017.
the Developed Pharmaceutical company ViiV Healthcare Tivikay is approved byto Russian Federation since 2014. The memorandum of cooperation between companies by JSC Viiv Heosker Trading and Serdix was signed on May 25, 2016 in the presence of the mayor Moscow Sergey Sobyanin.
According to data of the British companies GlaxoSmithKline, the combination of Tivikay with the lamivudiny can yield the same positive result, as well as at traditional therapy of HIV by three preparations.
of Tivikay – inhibitor integrazy new generation – can be applied as at adults who only began HIV infection treatment, and at those who already received therapy. Management approval on products and to drugs of United States of America (Food and Drug Administration, FDA) the preparation received in August, 2013. According to the forecast of an analytical portal of DrugAnalyst, annual sales proceeds Tivikaya in the world by 2019 will make $3,2 billion. Important property of a preparation is low level of intermedicinal interactions that allows to combine successfully it practically with all preparations applied to treatment of accompanying pathologies (tuberculosis, virus hepatitises).
GlaxoSmithKline– the British pharmaceutical company, created in 2000 by association GLAXO WELLCOME UK LTD Plc and SmithKline Beecham Plc. Glaxo makes preparations for treatment of asthma, a cancer, infections, mental disorders, diabetes and so forth. The revenue of companies in 2015 made $9,12 billion, and profit – $2,13 billion